title: Rheumatoid arthritis in the developing world.
abstract: The general impression is that rheumatoid arthritis (RA) has a lower prevalence and a milder course in developing countries. Epidemiological studies from different regions show that varying prevalence is possibly related to urbanization. The data suggest that where severe disability does occur, it presents a significant health challenge because of scarce medical and social resources. Disease-modifying anti-rheumatic drugs (DMARDs) remain the mainstay of therapy to alter the natural history of the disease. New therapies are unlikely to be of general benefit in the developing world because of financial constraints and increased risk of infections, particularly tuberculosis, associated with the use of tumour necrosis factor-alpha blockers. Instead, future research in poorer communities should be directed at assessing the burden of disease, the role of early aggressive therapy with DMARDs in combination with glucocorticoids for the majority of patients with RA, and finally, sourcing targeted biological therapies through clinical trials and grants for compassionate use in patients with refractory disease.
authors.affiliation: Division of Rheumatology, Department of Medicine, Groote Schuur Hospital and University of Cape Town, J47 Old Main Building, Observatory, Cape Town 7925, South Africa. kallaa@iafrica.com
authors.forename: Asgar Ali
authors.initials: AA
authors.lastname: Kalla
authors.forename: Mohammed
authors.initials: M
authors.lastname: Tikly
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology*; D003906:Developing Countries; D006801:Humans; D015995:Prevalence
chemical_list: D018501:Antirheumatic Agents